|
|
 |
| Preliminary Scientific Program |
 |
|
|
|
Thursday March 13, 2014 |
|
19:00-20:00 |
Welcome Reception
 |
|
|
Friday, March 14, 2014 |
|
|
Hall A |
|
09:00-10:30 |
Lessons to Learn from CV Outcome Studies
Chairs: J. Davidson, USA; I. Raz, Israel; D. Abouganem, Panama and
E. Mendoza, Panama |
|
09:10-09:30 |
SAVOR
P. Home, UK  |
|
09:30-09:50 |
ORIGIN
W. Cefalu, USA |
|
09:50-10:10 |
ACCORD
G. Grunberger, USA |
|
10:10-10:30 |
Discussion |
|
10:30-11:00 |
Coffee Break |
|
|
Hall A |
Hall B |
Hall C |
|
11:00-12:30 |
Can we Achieve Durable Therapy for A1C by Triple Therapy?
| Chair: N. Napoli, Italy |
|
|
11:05-11:25
Should we Aim to Cure Diabetes?
N. Napoli, Italy
|
|
Triple Therapy
11:25-11:40
Yes: R.A. DeFronzo, USA
|
|
11:40-11:55
No: I. Raz, Israel
|
|
11:55-12:15
Controversies in the Treatment of Diabetic Neuropathy
A. Odriozola, Spain
|
|
12:15-12:30
Discussion |
|
Session 3
Hypertension Treatment
| Chair: E. Grossman, Israel and Prof. H. Shehadeh |
|
Treatment of Hypertension in Type 2 Diabetes: Diuretics
11:05-11:20
Yes: E. Grossman, Israel
|
|
11:20-11:35
No: G. Waisman, Argentina
|
|
11:35-11:55
BP in Diabetes
G. Bakris, USA
|
|
11:55-12:15
New Oppportunities for Kidney Protection in Diabetes
A. Solini, Italy
|
|
12:15-12:30
Discussion |
|
Session 4
Obesity
|
Chair: E. Gruber De Bustos, Venzuela and
S. Klein, USA |
|
|
11:05-11:25
Obesity Therapy: When, Why and How?
S. Klein, USA
|
|
11:25-11:45
Overview on the New Drugs for Obesity
V. Hainer, Czech Republic
|
|
11:45-12:05
Obesity, Diabetes, Dyslipidemia and Hypertension: Translating Basic Science to Clinical Practice
E. Mendoza, Panama
|
|
12:05-12:30
Discussion |
|
|
12:30-13:30 |
Lunch Break |
|
13:30-15:00 |
Session 5
Hospitalization
| Chair: S. Heller, UK |
|
|
Increased Morbidity and Mortality
13:35-13:50
Yes: G. Umpierrez, USA
|
|
13:50-14:05
No: J. Mesa, Mexico
|
|
14:05-14:30
Should we Normalize Blood Glucose?
S. Heller, UK
|
|
14:30-15:00
Discussion |
|
Session 6
Blood Glucose Targets
| Chair: R. Lyra, Brazil |
|
|
Glucose Targets:
Should we Change Them?
13:35-13:50
Yes: B. Itzhak, Israel
|
|
13:50-14:05
No: G.C. Aylwin, Chile
|
|
Should we start with combination therapy?
14:05-14:20
Yes: R. Lyra, Brazil
|
|
14:20-14:35
No: I. Raz, Israel
|
|
14:35-15:00
Discussion |
|
Session 7
Bariatric Surgery
| Chair: L. Van Gaal, Belgium |
|
|
13:35-13:50
Bariatric Surgery and T2D: Are Their Therapeutic Weight Loss Independent Effects?
S. Klein, USA
|
|
13:50-14:05
Long Term Safety and Efficacy of Procedures
R. Cohen, Brazil
|
|
Which is the Best Procedure for Diabetic Patients?
14:05-14:20
Sleeve gastrectomy
L. Van Gaal, Belgium
|
14:20-14:35
Gastric Bypass
R. Cohen, Brazil
|
|
14:35-14:50
Endoscopic Therapy
F.J Lavalle-González, Mexico
|
|
14:40-15:00
Discussion |
|
|
15:00-15:30 |
Guided Poster Tour - Poster Tour Area |
|
15:30-17:00 |
Industry Plenary
|
|
17:00-17:30 |
Coffee Break |
|
17:30-19:00 |
Industry Plenary |
|
|
Saturday, March 15, 2014 |
|
|
Hall A |
Hall B |
Hall C |
|
08:00-9:30 |
Session 8
Diagnosis of Diabetes and Its Complications
| Chair: P. Home, UK |
|
|
Should we Base Diabetes Diagnosis on A1C?
08:05-08:25
Advantages:
J. Tuomilehto, Finland
|
|
08:25-08:45
Disadvantages:
E. Standl, Germany
|
08:45-09:05
Why are our Current Therapies of Such Limited Efficacy?
P. Home, UK
|
|
09:05-09:30
Discussion |
|
Redefining the Treatment of Type 2 Diabetes
| Chair: J. Davidson, USA |
|
08:10-08:40
A New Focus on the Pathophysiology of Type 2 Diabetes
R.A. DeFronzo, USA
|
|
08:40-09:10
SGLT-2 Inhibition:
Efficiacy and Safety
S. Del Prato, Italy
|
|
09:10-09:30
Discussion |
|
Diabetes Algorithm
| Chair: L. Litwak, Argentina |
|
|
Do we Need Regional/Local Algorithms/Guidelines?
08:05-08:25
No, ADA/EASD and/or AACE are Universally Accepted
L. Litwak, Argentina
|
|
08:25-08:45
Yes, ALAD is more Appropriate
P. Aschner, Colombia
|
08:45-09:05
We Don't Need Them at All
L. Zagury, Brazil
|
|
09:05-09:30
Discussion |
|
|
09:30-10:00 |
Coffee Break |
|
10:00-11:00 |
Industry Plenary
|
| 11:00-12:00 |
Industry Plenary
Present and Future of Diabetes Therapy
|
|
12:00-13:00 |
Lunch Break |
|
13:00-14:30 |
Session 11
Individual Approach
| Chair: J. Tuomilehto, Finland and N. Barengo, Colombia |
|
Can we Prevent Dementia/Alzheimer's Disease?
13:05-13:20
Yes: J. Tuomilehto, Finland
|
13:20-13:35
No: N. Barengo, Colombia
|
|
Should we quantify A1C parameters?
13:35-13:50
Yes: I. Raz, Israel
|
13-50-14:05
No: C. Belzarena, Uruguay
|
|
14:05-14:30
Discussion |
|
Session 12
Emerging Therapeutic Targets for T2DM
| Chair: R. DeFronzo, USA |
|
13:05-13:25
The Role of the Kidney in Glucose Homeostasis
R.A. DeFronzo, USA
|
|
13:25-13:45
Targeting the Kidney: A Novel Approach to Diabetes Therapy
L. Van Gaal, Belgium
|
13:45-14:05
Safety Concerns
J. Davidson, USA
|
|
14:05-14:30
Discussion |
|
Session 13
Can we Improve CV Outcome
| Chair: P. Aschner, Colombia and A. Milech, Brazil |
13:05-13:20
Diabetes and Hypoandrogenism
C. Musso, Argentina
|
|
13:20-13:35
Blood Pressure
G. Waisman, Argentina
|
|
13:35-13:50
Lipids
P. Aschner, Colombia
|
13-50-14:05
Sweeteners and Artificial Sweeteners
J. Mechanick, USA
|
|
14:05-14:30
Discussion |
|
|
14:30-15:00 |
Coffee Break |
|
15:00-16:30 |
Session 14
Diabetic Heart
| Chair: E. Standl, Germany |
15:05-15:25
Adipose Tissue
G. Márquez, Colombia
|
15:25-15:45
Role of Inflammation
E. Standl, Germany
|
|
15:45-16:05
Diabetes and Coronary
D. Pichel, Panama
|
|
16:05-16:30
Discussion |
|
Oral Presentations
| Chair: N. Napoli, Italy |
|
New Insulin U300: Glucose Control and Hypoglycaemia in Type 2 Diabetes People on Basal Insulin and OADS
(Edition 2)
F.J. Lavalle-González, Mexico |
|
Liraglutide Monotherapy Provides Superior Postprandial Plasma Glucose (PPG) Control After all Three Daily Meals Versus Sulphonylurea Monotherapy
A. Palacio Barrientos, Colombia |
|
Beta 2 Microglobulin and Subclinical Atherosclerosis in Type 2 Diabetes Mellitus without Renal Impairment
H.S. Kwon, South Korea |
|
Improvements in HBA1C and Body Weight with Liraglutide are Largely Independent of Diabetes Duration
S. Christensen, Denmark |
|
Robust Metabolic Improvement Observed with the Endoscopic, Duodenal-Jejunal Bypass Liner: 12 Month Data in Obese Type 2 Diabetes
R. Cohen, Brazil |
|
Session 15
Novel Therapy in Diabetes
|
Chair: C. Musso, Argentina and S. Del Prato, Italy |
15:05-15:25
PPAR Gama in T2D
R.A. Defronzo, USA
|
15:25-15:45
New GLP1 Analogs
S. Del Prato, Italy
|
15:45-16:05
Incretin Therapy- Safety Issues
G. Grunberger, USA
|
|
16:05-16:30
Discussion |
|
|
16:30-18:00
|
Hypoglycemia
| Chair: L. Litwak, Argentina |
|
Should we Prevent Mild Hypoglycemia?
16:35-16:50
Yes: L. Zagury, Brazil
|
16:50-17:05
No: S. Heller, UK
|
|
Are There Advantages to The New Insulin Analogs?
17:05-17:20
Yes: P. Raskin, USA
|
17:20-17:35
No: L. Litwak, Argentina
|
|
17:36-18:00
Discussion |
|
Session 17
Resistant Hypertension
| Chair: G. Bakris, USA |
|
Resistant Hypertension Approach
16:35-17:05
1- Pharmacological Intervention
G. Waisman, Argentina
|
17:05-17:35
2- Renal Denervation
G. Bakris, USA
|
|
17:35-18:00
Discussion |
|
Session 18
DPP4 Inhibitors: an Inclusive Treatment Option
| Chair: S. Del Prato, Italy |
|
16:35-16:55
DM2 and the Next Step - the Convenience of Combination to go Beyond Metformin
P. Aschner, Colombia
|
|
16:55-17:15
The Role of DPP-4 Inhibitors for the Treatment of T2DM
A. Solini, Italy
|
17:15-17:35
Cardiovascular Risk Control – the Critical Aim of T2D Management
S. Del Prato, Italy
|
|
17:35-18:00
Discussion |
|
|
|
Sunday, March 16, 2014 |
|
|
Hall A |
|
08:30-10:00 |
Session 19
Evidence Based Guidelines: European vs. USA
|
|
08:35-08:50 |
New guidelines for Hypertension: Europe vs. USA. What can we learn?
E. Grossman, Israel |
|
08:50-09:05 |
AACE Guidelines
J. Mechanick, USA |
|
09:05-09:10 |
Round Table Discussion
Chair: I. Raz, Israel |
|
09:10-09:20 |
Heart Failures in Diabetes
P. Pollack, USA |
|
09:20-09:25 |
Insulin
P. Home, UK |
|
09:25-09:30 |
SU
L. Litwak, Argentina |
|
09:30-09:35 |
DPP4 and GLP1
I. Raz, Israel |
|
09:35-09:40 |
SGLT2
J. Davidson, USA |
|
09:40-10:00 |
Discussion |
|
10:00-11:30
|
Session 20
The Place of Insulin/Incretin Therapy in Type 2 Diabetes
| Chair: E. Standl, Germany |
|
|
10:05-10:20 |
Incretin therapy
L. Litwak, Argentina |
|
10:20-10:35 |
Are Hepato-Specific insulins desirable?
P. Home, UK |
|
10:35-10:50 |
Early insulin therapy
P. Raskin, USA |
|
10:50-11:05 |
Late insulin therapy
E. Standl, Germany |
|
10:50-11:05 |
Discussion |
|
11:25-11:30 |
Closing Remarks
J. Davidson, USA; I. Raz, Israel; D. Abouganem, Panama and E. Mendoza, Panama |
| 11:30-12:00 |
Closing / Refreshments |
|
|
|
|
WebStudio.co.il